Daclatasvir/Olysio Combo Effectively Treats Hep C Genotype 1b
Tig said
Apr 2, 2014
I agree Malcolm. I also scratched my head when I realized that they specifically bring attention to the use and utilization of "Low" dose compounds. The actual amount these manufacturers will be out for the full strength dose will likely be insignificant in production cost. So this amounts to them getting more bang for their buck at and the real cost being borne by the patient and financially by the insurance provider. It's just an exercise to see how far they can stretch the supply. Maybe? I also agree with you that it's rather perplexing to see the use of these older NS blockers with Daclatasvir when better options exist. I'm sure like we've seen time and again, it's about market share and their desire to hoard as much of the glory for themselves as possible. However, if they could market it at an attractive price with 90+% SVR rates over a 8-12 week course and offer a single or two pill per day regimen, it might be widely accepted. At least until the next best thing comes along. As Jerry McGuire said, "Show me the money"!
Tig
mallani said
Apr 2, 2014
Hi Tig,
It's hard to understand why Companies persist with NS5A and NS3 blockers only. Surely by now we have seen that NS5B is the most critical site.
It's a shame to see a top-notch drug like Daclatasvir coupled with Olysio.
Tig said
Apr 1, 2014
Daclatasvir/Olysio Combo Effectively Treats Hep C Genotype 1b
A combination of low-dose daclatasvir and Olysio (simeprevir) cured a relatively high proportion of people with genotype 1b of hepatitis C virus (HCV), but just two thirds of a small group of genotype 1as. Findings from the LEAGUE-1 trial were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston and reported by aidsmap. March 31, 2014
I agree Malcolm. I also scratched my head when I realized that they specifically bring attention to the use and utilization of "Low" dose compounds. The actual amount these manufacturers will be out for the full strength dose will likely be insignificant in production cost. So this amounts to them getting more bang for their buck at and the real cost being borne by the patient and financially by the insurance provider. It's just an exercise to see how far they can stretch the supply. Maybe? I also agree with you that it's rather perplexing to see the use of these older NS blockers with Daclatasvir when better options exist. I'm sure like we've seen time and again, it's about market share and their desire to hoard as much of the glory for themselves as possible. However, if they could market it at an attractive price with 90+% SVR rates over a 8-12 week course and offer a single or two pill per day regimen, it might be widely accepted. At least until the next best thing comes along. As Jerry McGuire said, "Show me the money"!
Tig
Hi Tig,
It's hard to understand why Companies persist with NS5A and NS3 blockers only. Surely by now we have seen that NS5B is the most critical site.
It's a shame to see a top-notch drug like Daclatasvir coupled with Olysio.
Daclatasvir/Olysio Combo Effectively Treats Hep C Genotype 1b
A combination of low-dose daclatasvir and Olysio (simeprevir) cured a relatively high proportion of people with genotype 1b of hepatitis C virus (HCV), but just two thirds of a small group of genotype 1as. Findings from the LEAGUE-1 trial were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston and reported by aidsmap. March 31, 2014
http://www.hepmag.com/articles/daclatasvir_Olysio_2501_25398.shtml